Compare Stocks: LVTX, CYPH, KRRO, and CNTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.84 -4.7%	$2.28	$1.23 ▼ $3.82	$115.87M	-0.23	810,405 shs	2.41 million shs
CYPH Cypherpunk Technologies	$2.42 +6.6%	$0.94	$0.27 ▼ $3.70	$260.79M	0.33	8.50 million shs	16.90 million shs
KRRO Korro Bio	$12.24 +5.3%	$12.67	$5.20 ▼ $55.89	$180.25M	3.09	79,148 shs	78,429 shs
LVTX LAVA Therapeutics	$1.74	$1.72	$1.17 ▼ $1.83	$45.77M	0.5	187,834 shs	N/A

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-17.49%	-15.98%	-15.21%	-7.54%
CYPH Cypherpunk Technologies	0.00%	+41.52%	+259.16%	+366.46%	+734.77%
KRRO Korro Bio	0.00%	-5.19%	+0.99%	+14.18%	-52.98%
LVTX LAVA Therapeutics	0.00%	0.00%	0.00%	0.00%	+10.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.84 -4.7%	$2.28	$1.23 ▼ $3.82	$115.87M	-0.23	810,405 shs	2.41 million shs
CYPH Cypherpunk Technologies	$2.42 +6.6%	$0.94	$0.27 ▼ $3.70	$260.79M	0.33	8.50 million shs	16.90 million shs
KRRO Korro Bio	$12.24 +5.3%	$12.67	$5.20 ▼ $55.89	$180.25M	3.09	79,148 shs	78,429 shs
LVTX LAVA Therapeutics	$1.74	$1.72	$1.17 ▼ $1.83	$45.77M	0.5	187,834 shs	N/A

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-17.49%	-15.98%	-15.21%	-7.54%
CYPH Cypherpunk Technologies	0.00%	+41.52%	+259.16%	+366.46%	+734.77%
KRRO Korro Bio	0.00%	-5.19%	+0.99%	+14.18%	-52.98%
LVTX LAVA Therapeutics	0.00%	0.00%	0.00%	0.00%	+10.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	303.73% Upside
CYPH Cypherpunk Technologies	2.00	Hold	$1.60	-33.88% Downside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	36.55% Upside
LVTX LAVA Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest LVTX, CYPH, KRRO, and CNTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$1.60
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/19/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$0.90 ➝ $1.60
8/17/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
7/31/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/9/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/6/2026	KRRO Korro Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/3/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$60K	1,931.08	N/A	N/A	$0.43 per share	4.28
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.29 per share	N/A
KRRO Korro Bio	$6.39M	28.22	N/A	N/A	$7.01 per share	1.75
LVTX LAVA Therapeutics	$4.99M	9.17	N/A	N/A	$1.06 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
CYPH Cypherpunk Technologies	$4.82M	$0.56	4.32	N/A	N/A	N/A	-20.76%	-19.48%	N/A
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$0.86	N/A	N/A	N/A	N/A	-107.63%	-35.06%	N/A

Latest LVTX, CYPH, KRRO, and CNTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/12/2026	Q2 2026	CYPH Cypherpunk Technologies	N/A	$0.18	N/A	$0.18	N/A	N/A
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	2.37	2.37
CYPH Cypherpunk Technologies	N/A	79.19	79.19
KRRO Korro Bio	N/A	9.55	9.55
LVTX LAVA Therapeutics	N/A	12.27	12.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
CYPH Cypherpunk Technologies	30.46%
KRRO Korro Bio	13.18%
LVTX LAVA Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
CYPH Cypherpunk Technologies	3.50%
KRRO Korro Bio	4.80%
LVTX LAVA Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	62.97 million	48.74 million	Optionable
CYPH Cypherpunk Technologies	40	107.76 million	103.99 million	Optionable
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable

LVTX, CYPH, KRRO, and CNTB Headlines

Recent News About These Companies

Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69

November 16, 2025 | defenseworld.netD

LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq

November 13, 2025 | globenewswire.com

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

November 10, 2025 | globenewswire.com

Insider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells 690,239 Shares of Stock

October 21, 2025 | insidertrades.com

Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

October 20, 2025 | prnewswire.com

LAVA Therapeutics N.V. Announces Amendment to Tender Offer and Extension of Extraordinary General Meeting Date

October 17, 2025 | quiverquant.comQ

LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells $73,436.44 in Stock

October 16, 2025 | insidertrades.com

LAVA Therapeutics N.V. Stock (LVTX) Opinions on Insider Sales and Acquisition Delays

October 11, 2025 | quiverquant.comQ

Insider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells 28,954 Shares of Stock

October 11, 2025 | insidertrades.com

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

September 30, 2025 | globenewswire.com

LAVA Therapeutics N.V. (LVTX) - Yahoo Finance

August 20, 2025 | finance.yahoo.com

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

August 8, 2025 | prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)

August 7, 2025 | prnewswire.com

Jefferies Downgrades LAVA Therapeutics N.V. (LVTX)

August 5, 2025 | msn.com

LAVA Therapeutics Shares Climb on Buyout Deal with XOMA Royalty

August 4, 2025 | msn.com

XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics

August 4, 2025 | msn.com

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

August 4, 2025 | businesswire.com

LAVA Therapeutics Shareholders Approve Key Proposals in Meeting

June 13, 2025 | tipranks.com

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

May 16, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, CYPH, KRRO, and CNTB Company Descriptions

Connect Biopharma NASDAQ:CNTB

$1.84 -0.09 (-4.66%)

As of 09/4/2026 04:00 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Cypherpunk Technologies NASDAQ:CYPH

$2.42 +0.15 (+6.61%)

As of 09/4/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Korro Bio NASDAQ:KRRO

$12.24 +0.62 (+5.34%)

As of 09/4/2026 04:00 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

LAVA Therapeutics NASDAQ:LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LVTX, CYPH, KRRO, and CNTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LVTX, CYPH, KRRO, and CNTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LVTX, CYPH, KRRO, and CNTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, CYPH, KRRO, and CNTB Company Descriptions

Connect Biopharma NASDAQ:CNTB

Cypherpunk Technologies NASDAQ:CYPH

Korro Bio NASDAQ:KRRO

LAVA Therapeutics NASDAQ:LVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LVTX, CYPH, KRRO, and CNTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LVTX, CYPH, KRRO, and CNTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LVTX, CYPH, KRRO, and CNTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, CYPH, KRRO, and CNTB Company Descriptions

Connect Biopharma NASDAQ:CNTB

Cypherpunk Technologies NASDAQ:CYPH

Korro Bio NASDAQ:KRRO

LAVA Therapeutics NASDAQ:LVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools